Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization
- PMID: 12614179
- DOI: 10.1177/153303460200100109
Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization
Abstract
Extracorporeal photochemotherapy (ECP), or photopheresis, was originally introduced for the management of patients with cutaneous T cell lymphoma (CTCL). Today, ECP remains the only FDA approved tumor-targeting selective immunotherapy for the treatment of any cancer. The key cellular events permitting ECP-induced anti-tumor immunity against CTCL are the induction of apoptotis in the malignant T cells, and the induction of monocyte-to-dendritic cell (DC) differentiation. In standard ECP, leukocytes extracorporeally exposed to psoralen and ultraviolet A light (UVA) are circulated back to the patient. However, recent findings suggest that co-incubation of these cells prior to re-infusion allows for more efficient phagocytosis and processing of the apoptotic malignant T cells by the newly formed DCs. Moreover, such a co-incubation step permits the direct external manipulation of this system and the design of strategies to augment the production of tumor-loaded DCs. These considerations have led to the development of Transimmunization, so named because it causes transfer of tumor antigens to newly formed dendritic cells capable of initiating immunization against the tumor cells, as the replacement technology for ECP. We will review the scientific understanding of ECP and explain how this can lead a more efficient, potentially broadly applicable, immunotherapy for cancer.
Similar articles
-
Cutaneous T cell lymphoma: the helping hand of dendritic cells.Ann N Y Acad Sci. 2001 Sep;941:1-11. Ann N Y Acad Sci. 2001. PMID: 11594563 Review.
-
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells.Transfus Apher Sci. 2016 Aug;55(1):146-52. doi: 10.1016/j.transci.2016.06.001. Epub 2016 Jun 6. Transfus Apher Sci. 2016. PMID: 27317354
-
Extracorporeal photochemotherapy induces bona fide immunogenic cell death.Cell Death Dis. 2019 Aug 2;10(8):578. doi: 10.1038/s41419-019-1819-3. Cell Death Dis. 2019. PMID: 31371700 Free PMC article.
-
Transimmunization, a novel approach for tumor immunotherapy.Transfus Apher Sci. 2002 Jun;26(3):205-16. doi: 10.1016/s1473-0502(02)00014-9. Transfus Apher Sci. 2002. PMID: 12126207 Review.
-
The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.Transfus Apher Sci. 2012 Apr;46(2):195-202. doi: 10.1016/j.transci.2011.10.016. Epub 2011 Nov 8. Transfus Apher Sci. 2012. PMID: 22067605 Review.
Cited by
-
European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2693-2716. doi: 10.1111/jdv.16890. Epub 2020 Oct 6. J Eur Acad Dermatol Venereol. 2020. PMID: 33025659 Free PMC article.
-
Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.Oncoimmunology. 2020 May 13;9(1):1758869. doi: 10.1080/2162402X.2020.1758869. Oncoimmunology. 2020. PMID: 32566387 Free PMC article.
-
Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.J Invest Dermatol. 2014 Nov;134(11):2814-2822. doi: 10.1038/jid.2014.206. Epub 2014 Apr 29. J Invest Dermatol. 2014. PMID: 24780929
-
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells.Blood. 2008 Aug 15;112(4):1515-21. doi: 10.1182/blood-2007-11-125542. Epub 2008 Apr 14. Blood. 2008. PMID: 18411417 Free PMC article.
-
FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma.Mol Imaging Biol. 2008 Mar-Apr;10(2):74-81. doi: 10.1007/s11307-007-0127-y. Epub 2008 Jan 15. Mol Imaging Biol. 2008. PMID: 18196347
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical